Please use this identifier to cite or link to this item:
Title: Factor C for treating gram-negative bacterial infection
Authors: DING, JEAK L. 
Issue Date: 10-May-2011
Citation: DING, JEAK L.,HO, BOW,TAN, NGUAN S. (2011-05-10). Factor C for treating gram-negative bacterial infection. ScholarBank@NUS Repository.
Abstract: Recombinant fragments of Factor C are disclosed. These proteins and peptides show great potency in recognizing, binding to, neutralizing and removing endotoxin. These molecules can thus be used for anti-microbial, anti-endotoxin, and anti-sepsis therapy. SSCrFCES is a 38 kDa protein representing the LPS-binding domain of Factor C. The ability of SSCrFCES to bind lipid A was analyzed using an ELISA-based assay as well as surface plasmon resonance. Surface plasmon resonance similarly carried out for SSCrFC-sushi-1,2,3-GFP, SSCrFC-sushi-1GFP, and SSCrFC-sushi-3GFP confirmed their superior affinity for endotoxin. The 50% endotoxin-neutralizing concentration of SSCrFCES against 200 EU of endotoxin is 0.069 .mu.M, suggesting that SSCrFCES is an effective inhibitor of LAL coagulation cascade. Although partially attenuated by human serum, as low as 1 .mu.M of SSCrFCES inhibits the LPS-induced secretion of hTNF-.alpha. and hIL-8 by THP-1 and human pheripheral blood mononuclear cells with a potency more superior than polymyxin B. SSCrFCES is non-cytotoxic, with a clearance rate of 4.7 ml/minute. The LD.sub.90 of SSCrFCES for LPS lethality in mice is achieved at 2 .mu.M. These results demonstrate the endotoxin-neutralizing capability of SSCrFCES in vitro and in vivo, as well as its potential for use in the treatment of endotoxin-induced septic shock. Also embodied in this application is the use of the sushi peptides and their mutant derivatives as potent antimicrobials.
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
US7939492.PDF1.14 MBAdobe PDF



Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.